SYDNEY, Australia--(BUSINESS WIRE)--Hemispherx Biopharma, Inc. (AMEX: HEB) announced the initiation of a well-controlled Phase IIb trial in Australia of Ampligen®, an experimental TLR3 ligand shown to function as an immune system activator, in combination with trivalent seasonal influenza vaccine. The trial, expected to last for several months, is occurring in Australia’s winter season and focuses on populations at risk for virulent cases of influenza, especially those over the age of 60 years who may lack a robust immune system.
